Top Growth Stocks With High Insider Ownership In US For August 2024

In This Article:

The U.S. stock market has experienced significant volatility recently, with major indexes like the Dow Jones, S&P 500, and Nasdaq Composite seeing sharp declines amid a chip stock selloff and economic concerns. As investors navigate these turbulent times, growth companies with high insider ownership can offer unique advantages due to the confidence insiders have in their own businesses.

Top 10 Growth Companies With High Insider Ownership In The United States

Name

Insider Ownership

Earnings Growth

Atour Lifestyle Holdings (NasdaqGS:ATAT)

26%

21.9%

GigaCloud Technology (NasdaqGM:GCT)

25.9%

24.7%

PDD Holdings (NasdaqGS:PDD)

32.1%

21.6%

Victory Capital Holdings (NasdaqGS:VCTR)

12%

32.3%

Duolingo (NasdaqGS:DUOL)

15%

47.9%

Super Micro Computer (NasdaqGS:SMCI)

14.3%

39%

Credo Technology Group Holding (NasdaqGS:CRDO)

14.4%

60.9%

Carlyle Group (NasdaqGS:CG)

29.2%

23.6%

EHang Holdings (NasdaqGM:EH)

32.8%

74.3%

BBB Foods (NYSE:TBBB)

22.9%

94.7%

Click here to see the full list of 182 stocks from our Fast Growing US Companies With High Insider Ownership screener.

We'll examine a selection from our screener results.

Southern California Bancorp

Simply Wall St Growth Rating: ★★★★★☆

Overview: Southern California Bancorp, with a market cap of $292.86 million, operates as the holding company for Bank of Southern California, N.A.

Operations: Revenue from commercial banking operations amounts to $87.33 million.

Insider Ownership: 23.1%

Earnings Growth Forecast: 102.1% p.a.

Southern California Bancorp, with substantial insider ownership, is positioned for significant growth. The company's earnings are forecast to grow over 100% annually, outpacing market expectations. Despite recent challenges like increased net charge-offs and reduced net income (US$0.19 million in Q2 2024 vs US$6.72 million a year ago), its revenue is expected to grow over 50% annually. Recent developments include a merger with California BanCorp and multiple additions to Russell indices, enhancing its market visibility.

NasdaqCM:BCAL Earnings and Revenue Growth as at Aug 2024
NasdaqCM:BCAL Earnings and Revenue Growth as at Aug 2024

Madrigal Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company with a market cap of $6.07 billion, focuses on developing therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.

Operations: Madrigal Pharmaceuticals, Inc. primarily focuses on developing therapeutics for non-alcoholic steatohepatitis (NASH) in the United States.